Sun Pharma to acquire Ocular Technologies

Our Bureau Mumbai | Updated on January 16, 2018 Published on October 26, 2016

Sun Pharmaceutical will acquire Ocular Technologies, Sarl (OTS) from a portfolio company of Auven Therapeutics, an international private equity company focused on therapeutic drugs.

OTS owns exclusive, worldwide rights to Seciera (cyclosporine A, 0.09% ophthalmic solution). Sun Pharma will pay Auven $ 40 million upfront, plus contingent development milestones and sales milestones as well as tiered royalty on sales of Seciera.

Seciera is currently in a Phase-3 confirmatory clinical trial for the treatment of dry eye disease.

Published on October 26, 2016
This article is closed for comments.
Please Email the Editor